Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | NT5E | P21589 | 2/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078424 | 0.92 | HDAC1 (0.58) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL27833436 | 0.90 | TLR9 (0.49) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL10262713 | 0.90 | HDAC1 (0.53) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL1114352 | 0.84 | HDAC1 (0.48) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL18114701 | 0.82 | NT5E (0.48) | HDAC1PIK3CANT5E | |
| SCHEMBL1114163 | 0.81 | STAT3 (0.50) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL25230525 | 0.81 | HDAC1 (0.50) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL17078418 | 0.81 | HDAC1 (0.47) | HDAC1PIK3R1PIK3CAMTORPIK3CD | |
| SCHEMBL2395003 | 0.80 | TLR7 (0.50) | HDAC1PIK3CAMTORNT5ETLR7 | |
| SCHEMBL30439903 | 0.80 | TLR7 (0.50) | HDAC1PIK3CAMTORNT5ETLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | HDAC1 445/4885PIK3R1 48/4885PIK3CA 3/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | HDAC1 298/4885PIK3R1 12/4885PIK3CA 1/4885 |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | HDAC1 445/4885PIK3R1 48/4885PIK3CA 3/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | HDAC1 298/4885PIK3R1 12/4885PIK3CA 1/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | HDAC1 277/4885PIK3R1 3/4885PIK3CA 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.